• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

    6/29/23 6:02:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email
    For Immediate Release:
    June 29, 2023

    Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.

    “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can cause life-threatening health issues due to increased risk of uncontrolled bleeding,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval represents an important advance in providing treatment options for patients with this bleeding disorder, and treatment with gene therapy may reduce the need for ongoing routine therapy.”

    Hemophilia A is a rare genetic bleeding disorder that occurs due to a mutation on the gene which produces factor VIII (FVIII), a protein that enables blood to clot. The disorder primarily affects males. This deficiency in FVIII causes affected individuals to have uncontrolled bleeding and bleed longer than people who do not have the condition. The frequency and severity of bleeding episodes depends on how much FVIII protein a person produces. Severe hemophilia A is characterized by especially low levels of FVIII (less than 1% in the blood) and represents about 60% of all cases. Severe hemophilia A may result in bleeding into vital body organs such as the kidneys and brain, which can be life-threatening if left untreated. Treatment for severe hemophilia A usually involves use of FVIII replacement therapy or an antibody-based medication to improve the ability of blood to clot and reduce the likelihood of bleeding.

    Roctavian is a one-time gene therapy product administered as a single dose by intravenous infusion. Roctavian consists of a viral vector carrying a gene for clotting Factor VIII. The gene is expressed in the liver to increase blood levels of FVIII and reduce the risk of uncontrolled bleeding. 

    The safety and effectiveness of Roctavian were evaluated in a multinational study in adult men 18 to 70 years of age with severe Hemophilia A who were previously treated with Factor VIII replacement therapy. Effectiveness was established based on results from a cohort of 112 patients followed up for at least 3 years after Roctavian treatment. Following the infusion, the mean annualized bleeding rate decreased from 5.4 bleeds per year at baseline to 2.6 bleeds per year. The majority of patients who received Roctavian received corticosteroids to suppress the immune system for the gene therapy to be effective and safe. Treatment response to Roctavian may decrease over time. 

    The most common adverse reactions associated with Roctavian included mild changes in liver function, headache, nausea, vomiting, fatigue, abdominal pain and infusion-related reactions. Close monitoring for infusion-related reactions and liver enzyme elevation is advised with Roctavian administration. In some cases, treatment with Roctavian was observed to increase FVIII activity levels above the normal limits. An increase in FVIII activity may increase the risk of thromboembolic events (blood clots that can cause harm by blocking blood flow). Introduction of the Roctavian product’s DNA sequence may carry the theoretical risk of developing hepatocellular carcinoma (liver cancer) or other cancers. No instances of thromboembolic events or cancers associated with Roctavian were observed in clinical studies. 

    This application received Orphan, Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Priority Review designations. 

    The FDA granted approval of Roctavian to BioMarin Pharmaceutical Inc.

    Roctavian is approved with the AAV5 DetectCDx, a companion diagnostic test intended to help health care providers identify patients who may benefit from receiving Roctavian to treat hemophilia A. The test was proven effective in detecting pre-existing anti-AAV5 antibodies, which may render the gene therapy less effective or ineffective. Clinical study data from hemophilia A patients who received Roctavian after being identified as eligible by the AAV5 DetectCDx (patients without pre-existing anti-AAV5 antibodies), supported the safety and effectiveness of the AAV5 DetectCDx for its intended use as a companion diagnostic to Roctavian. The FDA granted approval of the AAV5 DetectCDx to ARUP Laboratories.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Carly Kempler
    240-672-8872
    Consumer:
    888-INFO-FDA

    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings

    $BMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

      First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y)  Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2025. "During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth

      5/1/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

      SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playba

      4/17/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

      Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone. Safety results were consistent with the known profile of the medicine. PALYNZIQ is the first and only enzyme therapy approved to treat adults with PKU. Detai

      4/2/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

      For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

      6/29/23 6:02:12 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioMarin Pharmaceutical upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00

      2/24/25 8:15:22 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on BioMarin Pharmaceutical with a new price target

      Wolfe Research initiated coverage of BioMarin Pharmaceutical with a rating of Outperform and set a new price target of $95.00

      11/15/24 7:39:24 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical downgraded by William Blair

      William Blair downgraded BioMarin Pharmaceutical from Outperform to Mkt Perform

      10/30/24 6:37:15 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

      SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025. Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen. Prior to Horizon, Mr. Walbert served as president and chief executive officer of IDM Pharma, w

      2/24/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Financials

    Live finance-specific insights

    See more
    • BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

      First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y)  Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the first quarter ended March 31, 2025. "During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth

      5/1/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

      SAN RAFAEL, Calif., April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144International Dial-in Number: 646-968-2525Conference Call ID: 4327591 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Playba

      4/17/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

      Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Feb. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024.

      2/19/25 4:05:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Hubbard Cristin was granted 273 shares and sold $17,723 worth of shares (273 units at $64.92) (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/6/25 5:07:22 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GVP, Chief Accounting Officer Burkhart Erin sold $92,618 worth of shares (1,295 units at $71.52), decreasing direct ownership by 7% to 16,955 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      3/20/25 7:38:48 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GVP, Chief Accounting Officer Burkhart Erin covered exercise/tax liability with 823 shares and was granted 5,970 shares, increasing direct ownership by 39% to 18,252 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      3/18/25 7:53:01 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioMarin Pharmaceutical Inc.

      10-Q - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/2/25 12:33:47 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/1/25 4:08:18 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioMarin Pharmaceutical Inc.

      SCHEDULE 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      4/29/25 9:14:11 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

      SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      9/30/24 4:29:01 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

      SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      7/10/24 1:14:41 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioMarin Pharmaceutical Inc.

      SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      7/8/24 4:32:41 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care